Edgewise Therapeutics, Inc.

NasdaqGS:EWTX Stok Raporu

Piyasa değeri: US$4.5b

Edgewise Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Edgewise Therapeutics kazanç ve gelirin sırasıyla yıllık 8% ve 36.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 12.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -7.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

8.0%

Kazanç büyüme oranı

12.55%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi14.9%
Gelir büyüme oranı36.9%
Gelecekteki özkaynak getirisi-7.58%
Analist kapsamı

Good

Son güncelleme18 Jun 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Jun 05

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

Summary Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3. A robust cash position extends the runway to a potential EDG-7500 approval, while EWTX pivots entirely to its cardiovascular pipeline and advances EDG-15400 for HFpEF. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 12

Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 10

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Summary Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials. Despite the increased stock price, EWTX remains a buy due to its derisked status and potential success across multiple myosin inhibition programs. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Summary Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities. The global Becker Muscular Dystrophy market is expected to reach $1.28 billion by 2034. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 26

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. By way of example, Edgewise...
Seeking Alpha • Sep 19

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Summary I previously rated Edgewise Therapeutics a sell due to limited market potential and lack of clinical data for sevasemten. Sevasemten, Edgewise's lead drug, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular Dystrophy. Edgewise stock has surged over 50% today however on Phase 1 data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy and diastolic dysfunction. The positive Phase 1 data for EDG-7500 significantly impacts Edgewise's valuation, highlighting the importance of considering early-stage assets. There is a long path to a potential approval shot, however, and the reliability of a 7-patient data set is not sufficient for a "buy" recommendation at this time. One for the watchlist. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 12

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Edgewise...
Seeking Alpha • Aug 05

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Summary Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation. Read the full article on Seeking Alpha
Seeking Alpha • May 10

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

Summary Edgewise Therapeutics, Inc. reported its first quarter earnings, revealing a strong cash position of $532m and a net loss of $(28.5m). The company is advancing two clinical-stage programs, including a pivotal trial for Becker muscular dystrophy and a Phase 1 trial for hypertrophic cardiomyopathy for a second candidate. Sevasemten, the lead drug candidate, showed positive results in a two-year study for Becker muscular dystrophy, supporting the hypothesis that it can preserve and improve muscle function. An FDA Fast Track designation for sevasemten has triggered a bull run that has seen the share price gain by >250%. A lack of genuinely meaningful catalysts in 2024, and a lengthy wait until an application for approval can be made, make this a good time to sell, in my view, although long-term, there are signs the drug is approvable. Read the full article on Seeking Alpha
Analiz Makalesi • May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics...
Seeking Alpha • Feb 18

Edgewise Therapeutics: Behind The Massive Rally

Summary Edgewise Therapeutics' stock has rallied massively after receiving FDA designations for its lead asset, EDG-5506, which has a potential $750 million opportunity in BMD. The company is focused on developing precision medicines for severe genetic neuromuscular and cardiac disorders. Edgewise Therapeutics has recently raised additional capital and has four data readouts for EDG-5506 scheduled for 2024. A full investment analysis around Edgewise Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 07

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Aug 16

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Apr 28

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Jan 13

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 13

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics (NASDAQ:EWTX) announced Tuesday its plans to raise $100M in the underwritten public stock offering; price, size and other terms not yet determined. The Colorado-based biopharmaceutical company told underwriters will be granted an overallotment option to purchase up to an additional $15M shares. It comes right after Edgewise Therapeutics received FDA's approval for phase 2 trial of its experimental drug, EDG-5506, in children with muscular dystrophy. Stock is down 2% in pre-market trading.
Seeking Alpha • Aug 04

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Edgewise Therapeutics press release (NASDAQ:EWTX): Q2 GAAP EPS of -$0.32 beats by $0.02. Cash, cash equivalents and marketable securities of $248.4 million as of June 30, 2022

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:EWTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202855-191N/A-1627
12/31/202753-171-68-348
12/31/2026209-26-443-3018
3/31/2026N/A-176-149-148N/A
12/31/2025N/A-168-144-144N/A
9/30/2025N/A-157-133-132N/A
6/30/2025N/A-151-126-125N/A
3/31/2025N/A-146-119-118N/A
12/31/2024N/A-134-110-109N/A
9/30/2024N/A-124-110-109N/A
6/30/2024N/A-116-105-104N/A
3/31/2024N/A-106-99-98N/A
12/31/2023N/A-100-98-92N/A
9/30/2023N/A-89-86-77N/A
6/30/2023N/A-81-77-67N/A
3/31/2023N/A-76-72-63N/A
12/31/2022N/A-68-58-53N/A
9/30/2022N/A-61-53-50N/A
6/30/2022N/A-56-48-46N/A
3/31/2022N/A-51-41-40N/A
12/31/2021N/A-43-34-34N/A
9/30/2021N/A-36-29-29N/A
6/30/2021N/A-27-24-24N/A
3/31/2021N/A-21-18-18N/A
12/31/2020N/A-17-15-15N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EWTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: EWTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: EWTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: EWTX şirketinin gelirinin (yıllık 36.9% ) US pazarından (yıllık 12.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EWTX şirketinin gelirinin (yıllık 36.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EWTX 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/28 02:52
Gün Sonu Hisse Fiyatı2026/06/26 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Edgewise Therapeutics, Inc. 14 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Cory KasimovEvercore ISI
Paul ChoiGoldman Sachs
Debjit ChattopadhyayGuggenheim Securities, LLC